A Recipe For Start-Up Success With A Platform Technology

By Neela Patel and John Mulligan

Startup and privately held biotechnology companies with a broadly applicable technology face a market that awards higher valuations to assets than to platforms for drug discovery. Platform companies, therefore, face a fundamental problem — how to return money to investors in a reasonable time frame and simultaneously realize the appropriate value for their platform.